Testing the Right Target and Right Drug at the Right Stage

被引：420

作者：

Sperling, Reisa A. ^{[1
]}

Jack, Clifford R., Jr. ^{[2
]}

Aisen, Paul S. ^{[3
]}

机构：

[1] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Alzheimer Res & Treatment,Brigham & Womens Ho, Boston, MA 02446 USA

[2] Mayo Clin, Dept Radiol, Rochester, MN 55902 USA

[3] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA

来源：

SCIENCE TRANSLATIONAL MEDICINE | 2011年 / 3卷 / 111期

关键词：

MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; AMYLOID DEPOSITION; A-BETA; CSF BIOMARKERS; ASSOCIATION; MRI; RECOMMENDATIONS; PROGRESSION; PREDICTION;

D O I：

10.1126/scitranslmed.3002609

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Alzheimer's disease (AD) is the only leading cause of death for which no disease-modifying therapy is currently available. Recent disappointing trial results at the dementia stage of AD have raised multiple questions about our current approaches to the development of disease-modifying agents. Converging evidence suggests that the pathophysiological process of AD begins many years before the onset of dementia. So why do we keep testing drugs aimed at the initial stages of the disease process in patients at the end-stage of the illness?

引用

页数：5

共 36 条

[21] Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome [J].

Oddo, S ;

Billings, L ;

Kesslak, JP ;

Cribbs, DH ;

LaFerla, FM .

NEURON, 2004, 43 (03) :321-332

[22] Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab [J].

Ostrowitzki, Susanne ;

Deptula, Dennis ;

Thurfjell, Lennart ;

Barkhof, Frederik ;

Bohrmann, Bernd ;

Brooks, David J. ;

Klunk, William E. ;

Ashford, Elizabeth ;

Yoo, Kisook ;

Xu, Zhi-Xin ;

Loetscher, Hansruedi ;

Santarelli, Luca .

ARCHIVES OF NEUROLOGY, 2012, 69 (02) :198-207

[23] Cognition, Reserve, and Amyloid Deposition in Normal Aging [J].

Rentz, Dorene M. ;

Locascio, Joseph J. ;

Becker, John A. ;

Moran, Erin K. ;

Eng, Elisha ;

Buckner, Randy L. ;

Sperling, Reisa A. ;

Johnson, Keith A. .

ANNALS OF NEUROLOGY, 2010, 67 (03) :353-364

[24] Biochemical markers in persons with preclinical familial Alzheimer disease [J].

Ringman, J. M. ;

Younkin, S. G. ;

Pratico, D. ;

Seltzer, W. ;

Cole, G. M. ;

Geschwind, D. H. ;

Rodriguez-Agudelo, Y. ;

Schaffer, B. ;

Fein, J. ;

Sokolow, S. ;

Rosario, E. R. ;

Gylys, K. H. ;

Varpetian, A. ;

Medina, L. D. ;

Cummings, J. L. .

NEUROLOGY, 2008, 71 (02) :85-92

[25] 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study [J].

Rinne, Juha O. ;

Brooks, David J. ;

Rossor, Martin N. ;

Fox, Nick C. ;

Bullock, Roger ;

Klunk, William E. ;

Mathis, Chester A. ;

Blennow, Kaj ;

Barakos, Jerome ;

Okello, Aren A. ;

de Llano, Sofia Rodriguez Martinez ;

Liu, Enchi ;

Koller, Martin ;

Gregg, Keith M. ;

Schenk, Dale ;

Black, Ronald ;

Grundman, Michael .

LANCET NEUROLOGY, 2010, 9 (04) :363-372

[26] Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging [J].

Rowe, Christopher C. ;

Ellis, Kathryn A. ;

Rimajova, Miroslava ;

Bourgeat, Pierrick ;

Pike, Kerryn E. ;

Jones, Gareth ;

Fripp, Jurgen ;

Tochon-Danguy, Henri ;

Morandeau, Laurence ;

O'Keefe, Graeme ;

Price, Roger ;

Raniga, Parnesh ;

Robins, Peter ;

Acosta, Oscar ;

Lenzo, Nat ;

Szoeke, Cassandra ;

Salvado, Olivier ;

Head, Richard ;

Martins, Ralph ;

Masters, Colin L. ;

Ames, David ;

Villemagne, Victor L. .

NEUROBIOLOGY OF AGING, 2010, 31 (08) :1275-1283

[27] Increased Brain Atrophy Rates in Cognitively Normal Older Adults with Low Cerebrospinal Fluid Aβ1-42 [J].

Schott, Jonathan M. ;

Bartlett, Jonathan W. ;

Fox, Nick C. ;

Barnes, Josephine .

ANNALS OF NEUROLOGY, 2010, 68 (06) :825-834

[28] Resolving controversies on the path to Alzheimer's therapeutics [J].

Selkoe, Dennis J. .

NATURE MEDICINE, 2011, 17 (09) :1060-1065

[29] Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: A population-based study in 85-year-olds [J].

Skoog, I ;

Davidsson, P ;

Aevarsson, O ;

Vanderstichele, H ;

Vanmechelen, E ;

Blennow, K .

DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2003, 15 (03) :169-176

[30] Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup [J].

Sperling, Reisa A. ;

Jack, Clifford R., Jr. ;

Black, Sandra E. ;

Frosch, Matthew P. ;

Greenberg, Steven M. ;

Hyman, Bradley T. ;

Scheitens, Philip ;

Carrillo, Maria C. ;

Thies, William ;

Bednar, Martin M. ;

Black, Ronald S. ;

Brashear, H. Robert ;

Grundman, Michael ;

Siemers, Eric R. ;

Feldman, Howard H. ;

Schindler, Rachel J. .

ALZHEIMERS & DEMENTIA, 2011, 7 (04) :367-385

← 1 2 3 4 →